Congress targets inhalant abuse by banning high-concentration dusters

What it does

This bill directs the Consumer Product Safety Commission to classify certain refrigerant gases (HFC-152a and HFC-134a) used in compressed air dusters as hazardous substances and ban duster products containing more than 18 mg of these chemicals. The bill aims to prevent inhalant abuse by making dusters harder to obtain for that purpose, while exempting FDA-regulated drugs and allowing the CPSC to add other harmful propellants to the ban list.

Why we flagged it

The bill's operative mechanism—banning high-concentration duster products and empowering the CPSC to regulate propellants—directly addresses inhalant abuse as a public-health problem. The 18 mg threshold and stockpile-prevention language are technical safeguards, not hidden riders.

What the text implies

• The 18 mg threshold may effectively eliminate most commercial duster products currently on the market, potentially disrupting the cleaning-supply industry's existing product lines and forcing reformulation or substitution with alternative propellants.
• The stockpile prohibition (capping manufacture/import at 105% of base-period volume) may create supply-chain bottlenecks if demand for compliant dusters exceeds the cap, potentially raising prices for legitimate users.
• The CPSC's open-ended authority to add 'additional harmful propellants' by regulation creates ongoing regulatory uncertainty for manufacturers and may lead to successive bans on replacement chemicals, incentivizing industry to develop non-inhalable propellant technologies.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill targets a genuine public-health harm—inhalant abuse of dusters, which causes acute intoxication, organ damage, and death, particularly among youth. Restricting access to high-concentration dusters reduces harm without eliminating the legitimate cleaning function (products under 18 mg remain legal). The mechanism is transparent and narrowly tailored to the stated purpose.

Who stands to gain

• manufacturers of alternative propellant technologies (e.g., hydrofluoroolefins, hydrofluoropolyether
• pharmaceutical and medical-device companies (exempted from the ban, may see increased demand for FDA
• consumer-safety advocacy organizations (may receive funding or support for enforcement/monitoring)

Named in the bill

Consumer Product Safety Commission (CPSC), Food and Drug Administration (FDA), HFC-152a (1,1-difluoroethane), HFC-134a (1,1,1,2-tetrafluoroethane), Federal Hazardous Substances Act

Where it stands

1 cosponsor: 1 Democrats.

• Jul 15, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 15, 2026 — Referred to Senate Committee on Commerce, Science, and Transportation · Congress.gov: “Read twice and referred to the Committee on Commerce, Science, and Transportation”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.